In late May, BDR had sought the approval of India’s drug regulator to make and sell remdesivir in India without entering into an arrangement with Gilead. The Mumbai-based company has now signed a contract to make the drug for Cipla, which is one of the licensed companies.
– Stocks-Markets-Economic Times
